PRODUCTION OF CONSTRUCTED CELLS FOR ADOPTIVE CELL THERAPY Russian patent published in 2022 - IPC C12N5/783 C12N15/867 A61K35/17 A61P37/00 

FIELD: biotechnology; cell biology.

SUBSTANCE: present invention relates to biotechnology and cell biology, in particular to methods for transduction of T-cells and methods for adoptive cell therapy. For the implementation of methods for transduction of T-cells, first, a retroviral vector particle, for example of a lentiviral vector, is incubated, containing recombinant nucleic acid encoding a heterologous molecule, with a composition containing T-cells. Then, the composition obtained at the first stage is incubated ex vivo in the presence of stimulating agents capable of activating T-cells. After that, a signal is induced by means of TCR complex, or T-cell proliferation is induced. At the same time, the first stage is started not late than 24 hours after taking a sample in an individual. In this case, the initial composition was not subjected to ex vivo stimulation, including incubation in the presence of agents capable of activating T-cells. The incubation at the final stage is carried out during not late than 10 days after the first incubation stage.

EFFECT: present invention allows for improvement strategies of transduction of cell populations in vitro for a possibility of their use in researches, diagnostics, and therapy.

90 cl, 3 dwg, 1 tbl, 2 ex